BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• BioMidwest

  NAI Release: NAI Launches Quality Event in Suzhou, China

  The purpose of this event is to promote quality awareness and provide continuing education on quality systems and processes at NAI.

  December 7, 2017

   · 

  3 min read
• Drug Development

  Zealand Pharma Initiates the Pivotal Phase III Trial With Dasiglucagon for the Treatment of Severe Hypoglycemia in Diabetes

  Dasiglucagon is a potential first-in-class soluble glucagon analog invented and developed by Zealand Pharma.

  December 7, 2017

   · 

  4 min read
• Drug Development

  INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis

  Using standard intramuscular injection as comparator, company’s Phase 1 clinical trial enrolls first patient.

  December 7, 2017

   · 

  3 min read
• Fibrocell Announces Pricing of $10.5M Underwritten Public Offering

  H.C. Wainwright & Co., LLC is acting as the sole book-running manager for the Offering.

  December 7, 2017

   · 

  4 min read
• Ablynx Will Host a Webcast to Discuss Additional Data From its Phase III Hercules Study of Caplacizumab in Acquired TTP Following ASH Late-Breaking Data Presentation

  The late-breaking data presentation will include positive topline results from the Phase III HERCULES study of caplacizumab announced on 2 October 2017 together with important data from additional analyses on the use of plasma exchange.

  December 7, 2017

   · 

  5 min read
• Biotech Beach

  US Compounding, a Subsidiary of Adamis Pharmaceuticals, Develops a Unique Compound to Manage Ulcers in Horses

  A study, utilizing US Compounding’s unique drug formulation, was conducted in approximately 50 race horses.

  December 7, 2017

   · 

  4 min read
• Pharm Country

  Cold Spring Harbor Laboratory Release: Next Generation Lyme Disease Tests Found Efficacious and Ready for Clinical Arena

  The 2016 Banbury Center meeting, chaired by Steven E. Schutzer, M.D., of Rutgers University-New Jersey Medical School, and John A. Branda M.D., of Harvard University, included participants from academia, public health, and medical industry.

  December 7, 2017

   · 

  3 min read
• 

  FDA

  Camber Spine Nabs FDA OK for Spira-C Open Matrix Cervical Interbody

  The SPIRA family of interbody implants represents the next generation of open architecture; 3-D printed, titanium implants designed to enhance fusion.

  December 7, 2017

   · 

  3 min read
• Policy

  Veeva CRM and Veeva OpenData Help the Life Sciences Industry Meet Compliance Requirements in Ohio

  Ohio law requires that all healthcare organizations (HCOs) have Terminal Distributor of Dangerous Drugs (TDDD) licenses to distribute the drugs that healthcare professionals (HCPs) are prescribing.

  December 7, 2017

   · 

  3 min read
• Biotech Beach

  CMS Issues Proposed National Coverage Determination of NGS IVDs Including Thermo Fisher Scientific’s Oncomine Dx Target Test

  Once implemented, the NCD would provide Medicare beneficiaries with reimbursable testing using Thermo Fisher Scientific’s multi-biomarker NSCLC diagnostic.

  December 7, 2017

   · 

  3 min read